Dr Claire Shepherd in the Sydney Brain Bank labs

Sydney Brain Bank

FACILITY INFORMATION

CASE COLLECTION AND CHARACTERISATION

Collection 

The brain donation occurs as soon as possible after death. This is done with the utmost care and respect by highly trained staff who perform the brain removals. The limited autopsies are usually carried out at the nearest participating hospital that has appropriate mortuary facilities. After the procedure, the tissue is transported back to the Sydney Brain Bank where it is processed and held.

Brain tissue arrives at the Sydney Brain Bank and is processed and stored in different ways as a means of offering the greatest options for researchers who may want to utilise the tissues for their experiments. This may include freezing some of the tissue so that it can be used for DNA extraction and/or biochemical studies. This is done in the shortest time period possible to ensure viability of most neurochemicals, proteins and RNAs. For participants with a strong family history of disease, the DNA may be screened for genes in which rare mutations have already been associated with neurodegeneration. The remaining tissue is fixed in formalin to preserve it for histological examination.

 

Characterisation

All brains undergo thorough microscopic examination to characterise each case according to the latest published diagnostic criteria (see list below). This information is communicated to the donors’ recruiting brain donor program. All tissue samples are de-identified to ensure anonymity of the donor.

 

Examples of common neuropathology

SBB Common neuropathology

Latest published neuropathologial diagnostic criteria

 

Alzheimer’s disease

Parkinson's Disease

Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Dickson DW et al;  Lancet Neurol. 2009 Dec;8(12):1150-7. Review. Erratum in: Lancet Neurol. 2010 Feb;9(2):140. Lancet Neurol. 2010 Jan;9(1):29

Dementia with Lewy Bodies (DLB)

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG et al; Neurology. 2005 Dec 27;65(12):1863-72. Review.

Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M; Neurology. 2005 Dec 27;65(12):1863-72. Review. Erratum in: Neurology. 2005 Dec 27;65(12):1992

Motor Neuron Disease

The genetics and neuropathology of amyotrophic lateral sclerosis. Al-Chalabi A, et al; Acta Neuropathol. 2012 Sep;124(3):339-52.

Multiple System Atrophy

Second consensus statement on the diagnosis of multiple system atrophy. Gilman S et al; Neurology. 2008 Aug 26;71(9):670-6.

Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Jellinger KA et al; Mov Disord. 2005 Aug;20 Suppl 12:S29-36.

Huntington’s disease

Neuropathological classification of Huntington’s disease. Vonsattel et al 1985. JNEN. 44:559-577

Primary age-related tauopathy (PART)

Primary age-related tauopathy (PART): a common pathology associated with human aging. John F. Crary, John Q. Trojanowski, Julie A. Schneider, Jose F. Abisambra, Erin L. Abner, Irina Alafuzoff6, Steven E. Arnold, Johannes Attems, Thomas G. Beach, Eileen H. Bigio, Nigel J. Cairns, Dennis W. Dickson, Marla Gearing, Lea T. Grinberg, Patrick R. Hof, Bradley T. Hyman, Kurt Jellinger, Gregory A. Jicha, Gabor G. Kovacs, David S. Knopman, Julia Kofler, Walter A. Kukull, Ian R. Mackenzie, Eliezer Masliah, Ann McKee, Thomas J. Montine, Melissa E. Murray, Janna H. Neltner, Ismael Santa-Maria, William W. Seeley, Alberto Serrano-Pozo, Michael L. Shelanski, Thor Stein, Masaki Takao, Dietmar R. Thal, Jonathan B. Toledo, Juan C. Troncoso, Jean Paul Vonsattel, Charles L. White 3rd, Thomas Wisniewski, Randall L. Woltjer, Masahito Yamada, and Peter T. Nelson. 2014 December ; 128(6): 755–766.

Aging-related tau astrogliopathy (ARTAG)

Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL 3rd, Wisniewski T, Woulfe JM, Yamada M, Dickson DW. Acta Neuropathol. 2016 Jan;131(1):87-102.

Frontotemporal Lobar Degeneration

Frontotemporal Lobar Degeneration (FTLD)-TDP

A harmonized classification system for FTLD-TDP pathology. Mackenzie IR et al; Acta Neuropathol. 2011 Jul;122(1):111-3

Frontotemporal Lobar Degeneration (FTLD)-FUS

Distinct pathological subtypes of FTLD-FUS. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, Kretzschmar HA, Cairns NJ, Neumann M. Acta Neuropathol. 2011 Feb;121(2):207-18.

Corticobasal Degeneration (CBD)

Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I; Office of Rare Diseases of the National Institutes of Health. J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46.

Progressive Supranuclear Palsy (PSP)

Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105.

Globular Glial Tauopathy (GGT)

Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Ahmed Z, Doherty KM, Silveira-Moriyama L, Bandopadhyay R, Lashley T, Mamais A, Hondhamuni G, Wray S, Newcombe J, O’Sullivan SS, Wroe S, de Silva R, Holton JL, Lees AJ, Revesz T. Acta Neuropathol. 2011 Oct;122(4):415-28.

 

 

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

Brain and Knee Muscle Weakness Study

Why Does Quadriceps Weakness Persist after Total Knee Replacement? An Exploration of Neurophysiological Mechanisms Total knee replacement is a commonly performed surgery for treating end-staged knee osteoarthritis. Although most people recover well after surgery, weakness of the quadriceps muscles (the front thigh muscles) persists long after the surgery (at least for 12 months), despite intensive physiotherapy and exercise. Quadriceps muscle weakness is known to be associated with more severe pain and greatly affect daily activities. This study aims to investigate the mechanisms underlying weakness of the quadriceps muscles in people with knee osteoarthritis and total knee replacement. We hope to better understand the relationship between the changes of the brain and a loss of quadriceps muscle strength after total knee replacement. The study might be a good fit for you if you: Scheduled to undergo a total knee replacement; The surgery is scheduled within the next 4 weeks; Do not have a previous knee joint replacement in the same knee; Do not have high tibial osteotomy; Do not have neurological disorders, epilepsy, psychiatric conditions, other chronic pain conditions; Do not have metal implants in the skull; Do not have a loss of sensation in the limbs. If you decide to take part you would: Be contacted by the researcher to determine your eligibility for the study Be scheduled for testing if you are eligible and willing to take part in the study Sign the Consent Form when you attend the first testing session Attend 3 testing sessions (approximately 2 hours per session): 1) before total knee replacement, 2) 3 months and 3) 6 months after total knee replacement. The testing will include several non-invasive measures of brain representations of the quadriceps muscles, central pain mechanisms, and motor function and questionnaires. Will I be paid to take part in the research study? You will be reimbursed ($50.00 per session) for travel and parking expenses associated with the research study visits. If you would like more information or are interested in being part of the study, please contact: Name: Dr Wei-Ju Chang Email: w.chang@neura.edu.au Phone: 02 9399 1260 This research is being funded by the Physiotherapy Research Foundation.  
PROJECT